Assessing modeling methods for predicting clinical CYP3A induction: A collaborative effort among academic, government regulatory, and pharmaceutical industry scientists
Heidi J. Einolf, Ping Zhao, Scott R. Obach, Mohamad Shebley(AbbVie (United States)), Odette Odette A. Fahmi, Michael Sinz(Rutgers, The State University of New Jersey), Lei Zhang(Qingdao University), Christopher R. Gibson(United States Military Academy), J. Fernando Silva(Instituto Superior de Educação e Ciências), Liangfu Chen, Jashvant D. Unadkat(University of Washington)
Unknown
January 1, 2013
Cited by 0
Related Papers
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
|The AAPS Journal|2014|646
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
|Chemical Research in Toxicology|1998|312
Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole
|Oncogene|2006|211
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
|Antimicrobial Agents and Chemotherapy|2012|186